iOrganBio, an innovator in intelligent cell manufacturing, announced the appointment of Zhiping Pang, M.D., Ph.D., to its Scientific Advisory Board. Dr. Pang is a leading expert in human neuron biology, synaptic function, and the molecular mechanisms underlying neuropsychiatric and metabolic disorders. He has published more than 140 papers in top journals such as Nature, Science, Nature Neuroscience, and Nature Metabolism. He serves as the Henry Rutgers Professor of NeuroMetabolism and Professor of Neuroscience and Cell Biology at Rutgers Robert Wood Johnson Medical School, and directs the Center for NeuroMetabolism at Rutgers Health.
The appointment brings deep expertise in human neuron and synaptic biology to iOrganBio’s advisory board, which is critical as the field moves toward more human-relevant, non-animal systems. Pang's knowledge will help guide the company’s development of FDA-aligned New Approach Methodologies (NAMs) that aim to reduce reliance on animal testing. This bolsters iOrganBio’s position as a leader in AI-enabled, scalable human cell and organoid production.
iOrganBio’s platform, CellForge™, uses artificial intelligence and automation to consistently manufacture cells and organoids for in vitro modeling and cell therapies. The platform relies on the company’s functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver accuracy, efficiency, and quality for applications in disease modeling, regenerative medicine, and drug development.
For more information, visit iOrgan.Bio or follow the company on LinkedIn.
